Mindfulness practices associated with left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct-current stimulation (tDCS) have a therapeutic effect in women with chronic migraine.
Headache specialist was more likely to use triptans, while non-headache specialists and the headache specialist started prophylaxis at similar rates in eligible participants.
Alder BioPharmaceuticals has submitted a Biologics License Application to the FDA for eptinezumab, an investigational monoclonal antibody for migraine prevention.
Results suggest that it is important to develop interventions aimed at improving the quality of life in individuals with chronic migraine and to increase knowledge about headache and psychological consequences.
Acupuncture, neurostimulation, and other alternative treatments have been associated with up to a 50% reduction in headache days.
Patients in both groups were satisfied with their care.
Previous analysis showed that treatment reduced chronic migraine frequency.
Participants experienced a reduction in headache days as soon as 3 days post-treatment.
Treatment of chronic, but not episodic migraine with botulinum toxin has been added to the treatment guidelines.
